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Objective. A combination of intravenous clindamycin and oral tetracycline has been used for many years as a treatment for active
rheumatoid arthritis (RA), despite the absence of good evidence for its eﬃcacy. A single-blind pilot study of this therapy suggested
that a double-blind placebo-controlled trial was warranted. Methods. Patients with active RA were randomised in a 2:1 ratio to
receive active treatment or placebo for 25 weeks. The active treatment consisted of intravenous clindamycin in a reducing regime,
and oral tetracycline twice daily three times a week. 50 patients were to be recruited. The primary outcome measure was the
proportion of patients achieving an ACR20 response. Results. An interim statistical analysis was performed after 20 patients had
completed the study. Two patients in the active group achieved an ACR20 response, with none in the placebo group (NS). There
was a better ESR20 response in the placebo group (P = .02). There were no other signiﬁcant diﬀerences between the groups. The
results indicated that it was unlikely that a signiﬁcant diﬀerence in ACR20 response would emerge if the remaining 30 patients
were recruited. The trial was therefore halted. Conclusion. This antibiotic regime is unlikely to be a valuable therapy for active
rheumatoid arthritis.
1.Introduction
Many drugs are used to treat RA. These include nonsteroidal
anti-inﬂammatory drugs (NSAIDs), “second-line” drugs,
corticosteroids and biological agents. All of these therapies
have signiﬁcant drawbacks in terms of eﬃcacy, side eﬀects,
or cost [1, 2]. For many patients; therefore, current therapy
remains unsatisfactory, and there remains a need to ﬁnd
treatments that are eﬀective, well tolerated, and relatively
inexpensive.
There has been growing interest in the use of antibiotics
for the treatment of RA, notably tetracyclines [3]. These
were initially used by Brown et al. in uncontrolled studies
in patients with RA [4]. The original rationale for their
use was the hypothesis that RA may be caused by infection
with Mycoplasma or similar organisms [5]. This now seems
unlikely,andsubsequentstudieshavesuggestedotheractions
for this class of drug, including the inhibition of matrix met-
alloproteinases [6]. Three double-blind, placebo-controlled
trials of minocycline in active RA have shown signiﬁcant
improvement in most clinical and laboratory measurements
in the treatment group compared with the placebo group
[7–9]. In the treatment of early RA, minocycline has also
been shown to be superior to hydroxychloroquine [10] while
doxycycline has been shown to enhance the response to
methotrexate [11].
On the basis of other bacteria being a possible causative
or exacerbating agent in RA [4], a combination of intra-
venous (IV) clindamycin and oral tetracycline has been used
by some physicians for many years as a treatment for active
rheumatoid arthritis. However, apart from unpublished,
anecdotal reports, there was no controlled evidence for the
eﬃcacyofthisregime.Inviewofthis,weperformedasingle-
blind, controlled pilot study of this antibiotic combination
[12]. Half of the patients were given active treatment in
addition to their usual therapy, and half were given no2 International Journal of Rheumatology
additional treatment. For ethical reasons patients in this
latter group were not given a placebo, and all participants
knew into which group they had been allocated. The
treatment was given for a year, and patients were followed
up for a further six months.
Nine out of eleven patients in the treatment group
completed the ﬁrst 12 months of the study, while only three
of ten patients in the control group did (P<. 05). Patients
who withdrew did so because of lack of improvement in
their condition. Five patients in the treatment group had an
ACR20 response at 12 months, while none of the control
patients did (P<. 05). Improvement generally occurred
withinsixmonthsofstartingthetreatment.Furtherevidence
for the eﬃcacy of the treatment was that it was not well
maintained once it had been withdrawn. No signiﬁcant side
eﬀects were encountered.
These results suggested that this combined antibiotic
therapy might be useful in the management of active RA
although they could have been explained by a placebo
response to the therapy. They indicated that a double-blind,
placebo-controlled trial of the therapy was justiﬁed.
2. Patientsand Methods
2.1. Patients. Male and female patients aged between 18 and
80yearsattendingtheRheumatologyClinicatCharingCross
Hospital were invited to take part in the study. All had
classical RA of at least six months’ duration, as deﬁned by
the American College of Rheumatology classiﬁcation criteria
[13]. All patients had active synovitis, a disease activity score
(DAS28) of greater than 3.8 [14], and radiographic erosions.
All patients had “failed” methotrexate or sulphasalazine:
either they had had an inadequate response (as deﬁned
by persistence of active synovitis) to methotrexate (at least
7.5mg per week) or sulphasalazine (at least 1,000mg twice
daily) for at least three months or they had been unable
to take or tolerate either drug at the above doses. Patients
could be taking other second-line antirheumatic drugs (e.g.,
sulphasalazine, methotrexate, hydroxychloroquine, azathio-
prine, leﬂunomide, intramuscular gold, oral gold, or peni-
cillamine), but the dose of any of these had to have been
unchanged for at least three months. They could also be
on prednisolone, up to a maximum dose of 7.5mg per
day, unchanged for at least three months. Patients could be
taking NSAIDs and/or simple analgesics (e.g., paracetamol,
coproxamol, or codeine).
Exclusion criteria included severely incapacity (Stein-
brocker functional grade IV [15]), chronic/ recurrent infec-
tion (e.g., chronic bronchitis, recurrent sinusitis), other
infections, immunodeﬁciency, malignancy, inﬂammatory
bowel disease, other diarrhoeal states, other major illness,
history of adverse reactions to tetracycline, clindamycin, or
similar antibiotics, and pregnancy or lactation.
After recruitment, patients were randomly assigned in a
2:1ratiotooneoftwotreatmentgroups:GroupI(antibiotic
group) and Group II (control group).
2.2. Treatment Regime: General. The patients in Group I
received IV and oral antibiotics as below. Patients in Group
II received normal saline infusions and matched placebo
tablets, as detailed below. Apart from the antibiotic ther-
apy, the protocol for treatment (other drugs), assessment,
and withdrawal from the study was identical for the two
groups of patients. Patients were blinded as to which
group they had been randomised, as were all clinicians and
assessors.
2.3. Trial Drugs. The drug regime was the same as that
commonly used in clinical practice (Hornett G, personal
communication), and employed in the pilot study [12]. After
an initial assessment (see below), patients in Group I started
receiving IV infusions according to the regime in Table 1.
Each infusion was given slowly in 250mL normal saline over
half an hour. Patients in Group II received IV saline without
clindamycin according to the same regime. In addition,
patients took oral tetracycline 250mg (Group I) or placebo
(Group II) twice a day three times per week. This regime
was continued for each patient for 25 weeks. There were
a total of 18 IV infusions for each patient. The maximum
timebetweeninitialassessmentandtheﬁrstinfusionwasone
month.
2.4. Other Drugs. During the study, the doses of second-
line agents and prednisolone remained unaltered, if taken.
If more active treatment of the rheumatoid arthritis was
required, patients were oﬀered joint aspiration and intra-
articular injection of steroid (methylprednisolone 40–80mg
or hydrocortisone 12.5–25mg) into one or more inﬂamed
joints, up to a maximum of three injections. If further
steroid was required or it became necessary to use another
immunosuppressive drug, the patient left the study, and
the event was recorded as a treatment failure. Patients were
allowed to continue taking NSAIDs and/or simple analgesics
and to alter the doses of these as required.
2.5. Withdrawal. Patients were free to withdraw from the
study at any time and were withdrawn if this was thought
necessary for any other reason by the supervising clinician.
2.6. Assessments. Patients were assessed at the outset of the
study, and then every two months until the end of the study
(25 weeks), that is, four assessments in all. The following
were used:
2.6.1. Clinical. American College of Rheumatology (ACR)
Core Data Set [16]; this included the following:
(i) patient’s assessment of joint pain (visual analogue
scale);
(ii) patient’s global assessment of disease activity (visual
analogue scale);
(iii) assessor’s global assessment of disease activity (visual
analogue scale);
(iv) functional assessment completion of health assess-
ment questionnaire (HAQ) by patient;International Journal of Rheumatology 3
Table 1: Treatment and assessment regimes for patients in Group I (active treatment). Clindamycin infusions were given in 250 mL normal
saline over one hour. Patients in Group II (placebo) received placebo infusions of normal saline and placebo tablets according to the same
regime; they had the same assessment regime. bd: taken twice a day (morning and evening). × 3/wk: three times per week. Assessments: C,
clinical; L, laboratory.
Time Clindamycin infusion Tetracycline Assessment
CL
Day 1 300mg 250mg bd + +
Day 2 300mg none
Day 3 600mg 250mg bd
Day 4 600mg none
Day 5 900mg 250mg bd
Weeks 2–4 900mg per week 250mg bd × 3/wk
Weeks 5–8 900mg fortnightly 250mg bd × 3/wk
At week 9 ++
Weeks 9–16 900mg fortnightly 250mg bd × 3/wk
At week 17 ++
Weeks 17–24 900mg fortnightly 250mg bd × 3/wk
At week 25 ++
(v) number of swollen and number of tender joints
(determined by physical examination of 28 joints).
NSAID and analgesic use.
The dose of oral prednisolone, and all other drugs.
Any joints which had been injected with steroid during the
study were excluded from the assessment.
2.6.2. Laboratory. Standard blood tests (full blood count,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), and liver function tests)
Serum matrix metalloproteinase levels (MMP-1 and
MMP-3) were measured, using commercially available kits
(R&D Systems, Abingdon, UK). Urinary pyridinoline cross-
links (PYD) were detected using a speciﬁc monoclonal
antibody in a commercial kit (Metra, Quidel, San Diego,
Calif, USA) [17].
2.7. Outcome Measures. The primary outcome measure was
theachievementofanACR20%response[16]atsixmonths.
This was deﬁned as:
(i) >20% reduction in number of swollen and tender
joints;
(ii) >20% improvement in at least three out of ﬁve of the
following:
(a) CRP;
(b) patient’s assessment of joint pain (visual ana-
logue scale);
(c) patient’s global assessment of disease activity
(visual analogue scale);
(d) assessor’s global assessment of disease activity
(visual analogue scale);
(e) functional assessment completion of health
assessmentquestionnaire(HAQ)bythepatient.
Other outcome measures included the following:
(i) individual components of the ACR score, as above;
(ii) withdrawal from the study because of a greater than
20% deterioration according to ACR response;
(iii) number of intraarticular steroid injections given;
(iv) the use of NSAIDs and analgesics.
If withdrawal occurred for any reason, a ﬁnal clinical and
laboratory assessment was performed at this point.
2.8. Statistics
2.8.1. Randomization Ratio. A participant ratio of 2:1
between Groups I and II was chosen in order (i) to obtain
more information on adverse eﬀects in the treatment group,
(ii) to aid recruitment, and (iii) to reduce withdrawals from
the study.
2.8.2. Sample Size Calculations. The primary outcome mea-
sure was the proportion of patients who achieved an ACR
20% response. It was assumed that only 5% of the patients
receiving standard therapy would respond. A sample size of
30 patients in Group I (active treatment) and 15 patients in
Group II (placebo) would be suﬃcient to detect a response
rate of 50% in the active-treated group using the 5%
signiﬁcance level with a power of 80%. The patient numbers
were increased by approximately 10% to take account of
individuals dropping out of the study for reasons other than
disease progression. This gave 33 patients in Group I and 17
patients in Group II, and, therefore, a total of 50.
2.8.3. Statistical Analysis. The statistical analysis was restrict-
edtothemeasurementsatbaselineandsixmonths.Forthose
patients who withdrew from the study, measurements from
the ﬁnal assessment were used in the statistical analysis.4 International Journal of Rheumatology
Table 2: Baseline characteristics of each group.
Variable Placebo (n = 8) Active (n = 12)
Mean SD Mean SD
Assess 5.0 3.0 4.7 2.0
DAS 4.7 0.9 4.7 0.7
EMS 75 108 154 405
HAQ 1.7 0.4 1.3 0.7
C R P 1 21 52 31 9
E S R 2 91 62 61 6
Fatigue 6.6 1.6 6.3 1.5
Pain 4.2 2.7 5.2 1.9
Pt. assess 4.2 2.9 5.4 1.8
Swollen joints 11 4 12 5
Tender joints 6 3 7 3
Assess: physician global assessment, VAS; DAS: DAS disease activity score;
EMS: early morning stiﬀness; HAQ: HAQ disability score; Fatigue: fatigue
assessment, VAS; Pain: patient assessment of pain, VAS; Pt. assess: patient
global assessment, VAS; Swollen joints: swollen joint count; Tender joints:
tender joint count.
The proportion of patients who achieved an ACR 20%
response (relative to baseline) at six months were compared
in the two randomised groups, using Fisher’s exact test.
Patients who were withdrawn from the study were included
in this analysis as nonresponders.
For continuous outcome measures a two-sample t-test
was used to compare the change from baseline in the two
randomised groups.
2.9. Ethical Approval. Ethical approval for this project was
obtained from the Hammersmith Hospital Research Ethics
Committee.
3. Results
It had been planned to recruit 50 patients to the trial: 33
patients in Group I (active treatment) and 17 patients in
Group II (placebo). After the 20th patient had completed
the study, an interim statistical analysis was performed. This
analysis showed that in almost all outcome measures, there
was no trend towards a diﬀerence between active treatment
andplacebo.Thetrialwas,therefore,haltedatthispoint.The
following results are, therefore, those obtained on those 20
patients.
Twelve patients were randomised to active treatment and
8 to placebo treatment. Assessments were made at weeks 1,
8, 16, and 25. Week 1 was the start of treatment and week
25 the end of treatment. Table 2 summarises the baseline
characteristics of each group. The two randomised groups
were similar at baseline.
The primary outcome measure was the ACR20 response
at the end of treatment (week 25). Improvement was
calculated by comparing the value at week 25 with the
value at baseline (week 1). Improvements corresponded to
a decrease for each of the 7 variables. These comparisons
are summarised in Table 3. A total of 15 of the 20 patients
completed the 25 weeks of followup. Patients who did not
complete the treatment period were considered not to have
achieved a 20% improvement. Two patients in the active
group achieved an ACR20 response, while none of the
patients in the placebo group did (not signiﬁcant).
All ﬁve of the patients who did not complete the trial
were on active therapy. Three patients were withdrawn due
to disease progression, and two were withdrawn due to
protocol transgression. This diﬀerence in completion rates
was statistically signiﬁcant (P = .06). There was also a
signiﬁcant diﬀerence (P = .02) in the percentage of patients
with a 20% ESR response, with a higher improvement rate in
the placebo group.
The sample size calculation assumed that 5% of placebo
and 50% of active patients would achieve an ACR20
response, a diﬀerence in response rates of 45%. The 95%
conﬁdence interval for the (placebo-active) diﬀerence in
response rates was 38 to 4, which excludes a diﬀerence of
45%. The 95% conﬁdence interval for an ACR20 response
in the active treatment group was 2 to 48%, which excludes
the response rate of 50% used in the sample size calculation.
This made it very unlikely that there would be a statistically
signiﬁcant diﬀerence in ACR20 response between the two
groups if the trial were continued to completion and a total
of 50 patients recruited.
An analysis of covariance was performed to compare
the two treatments for the assessments at the end of trial,
includingthebaselinevalueasacovariate.Thisenabledcom-
parison of the ﬁnal status of the two groups after allowing for
their initial status. The results showed no discernable trend
towards a diﬀerence between the two groups.
For the whole cohort of 20 patients, there was signiﬁcant
correlation between levels of MMP-1 and HAQ score (P =
.02),MMP-3andCRP(P = .001),MMP-3andpatientglobal
assessment (P = .068), and PYD and HAQ (P = .054). There
was no signiﬁcant correlation between MMP-1, MMP-3, and
PYD levels, and any of the other measures of disease activity.
There was no signiﬁcant diﬀerence in the change in MMP-1,
MMP-3, or PYD levels between the two groups.
4. Discussion
Inthistrialweusedthesametreatmentregime—intravenous
clindamycin and oral tetracycline—as that employed in the
pilot study. Based on our power calculation, we had planned
to recruit 50 patients in a 2:1 ratio (active to placebo
treatment). However, after 20 patients had completed the
study, an interim statistical analysis showed that it would be
unlikely that a signiﬁcant diﬀerence would emerge between
the treatment groups if we were to recruit the remaining 30
patients. The trial was therefore halted.
The results reported here on the ﬁrst 20 patients did
show some diﬀerences between the two groups. Two out of
the 12 patients (17%) in the active treatment group (Group
I) showed an ACR20 response, while none of the patients
receiving placebo did (Group II). However, the conﬁdence
intervals were wide. If this trend were continued, we would
have had to recruit 126 patients in order for the diﬀerence to
become signiﬁcant.International Journal of Rheumatology 5
Table 3: Number and percentage of patients with an ACR20 response, together with the number of patients with a 20% improvement for
each core variable. 20 after each variable indicates 20% improvement.
Variable Placebo (n = 8) Active (n = 12) Placebo-active P value
Number % Number % Diﬀerence % 95% CI
A C R 2 0 002 1 7−17 −38 to 4 .5
Completed 8 100 7 58 42 14 to 70 .06
HAQ20 0 0 2 17 −17 −38 to 4 .5
VAS Assess.20 5 63 4 33 29 −14 to 72 .4
Pat. Pain20 1 13 3 25 −13 −46 to 21 .6
Pat. Dis. Assess.20 1 13 2 17 −4 −35 to 27 1.0
CRP20 3 38 4 33 4 −39 to 47 1.0
ESR20 5 63 1 8 54 17 to 91 .02
Swollen joint20 4 50 6 50 0 −45 to 45 1.0
Tender joint20 6 75 6 50 25 −16 to 66 .4
Against this trend, the results showed a higher number of
withdrawals due to disease progression in Group I compared
with Group II. There was a statistically signiﬁcant greater
improvement in ESR in Group II compared with Group I.
There are a number of possibilities to explain the
apparent lack of beneﬁt of the active treatment. It is likely
that receiving intravenous infusions on a regular basis has a
signiﬁcant placebo eﬀect. This could explain why there was
an apparent beneﬁt in the single-blind but not in the double-
blind study. It may be that a small number of patients with
RA do genuinely respond to the antibiotic therapy, but that
our study was underpowered to detect this. If this is the
case, it could be argued that the number needed to treat
would be too high for this to be a valuable therapy. Another
possibilityisthediﬀerenceinoralantibiotic:previousstudies
in this ﬁeld have generally used minocycline or doxycycline
[9–13], and the dose of tetracycline used in this trial
was comparatively low; in earlier studies, minocycline and
doxycycline have been given twice daily [9–13].
The literature shows robust evidence for the eﬃcacy of
various tetracycline-based antibiotic regimes in modifying
theactivityofrheumatoidarthritis.Theresultsofthepresent
trial would be consistent with the hypothesis that it is the
anti-inﬂammatory rather than the antibacterial activity of
tetracyclines that confers this beneﬁt.
The particular combination of clindamycin and tetra-
cycline used in this trial has been employed extensively in
clinical practice. However, the results indicate that it may not
be suitable for further study.
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